Organism: Homo sapiens
Gene: 39817_s_at
Selected probe(set): 39817_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39817_s_at (39817_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-2.8899622
Number of Samples:2 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-2.7417297
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 cell sample
	Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):2.553608
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS27a)
	CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):2.3458977
Number of Samples:6 / 5

Experimental	connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control	connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted).

Relative Expression (log2-ratio):2.3346958
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS5)
	CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):-2.2642794
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 DICER1(-/-) cell sample
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):2.0850382
Number of Samples:15 / 2

Experimental	uterine/pelvic pathology study 2 (pro. MCP)
	Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control	uterine/pelvic pathology study 2 (late se MCP)
	Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

Relative Expression (log2-ratio):-2.0198612
Number of Samples:2 / 2

Experimental	LPS study 4
	MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	mock treated MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells mock treated.

Relative Expression (log2-ratio):-1.9593811
Number of Samples:2 / 2

Experimental	LPS study 4 (shRNA contr.)
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	mock treated / transduced MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

Relative Expression (log2-ratio):-1.922183
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	tunicamycin study 2 (2ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---